Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction

Bibliography

• Kudlacek S, Schneider B, Woloszczuk W, Austrian Study Group on Normative Values of Bone Metabolism. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003;32:681-6
   PubMed Web of Science ®Google Scholar
• Speer G, Fekete BC, El Hadj Othmane T, Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant 2008;23:3256-62
   PubMed Web of Science ®Google Scholar
• Stepien E, Wypasek E, Stopyra K, Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin Biochem 2011;44:826-31
   PubMed Web of Science ®Google Scholar
• Kiechl S, Schett G, Wenning G, Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175-80
   PubMed Web of Science ®Google Scholar
• Kurnatowska I, Grzelak P, Kaczmarska M, Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. Nephron Clin Pract 2011;117:297-304
   Google Scholar
• Omland T, Ueland T, Jansson AM, Circulating osteoprotegerin levels and long term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008;51:627-33
   PubMed Web of Science ®Google Scholar
• Jono S, Ikari Y, Shioi A, Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-4
   PubMed Web of Science ®Google Scholar
• Kim BJ, Sung KC, Kim BS, Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and c reactive protein. Clin Sci (Lond) 2005;108:237-43
   PubMed Web of Science ®Google Scholar
• Cooke JP. Asymmetrical dimethylargine. The uber marker? Circulation 2004;109:1813-19
   PubMed Web of Science ®Google Scholar
• Zoccali C. Asymmetrical dimethylargine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006;24:611-19
   PubMed Web of Science ®Google Scholar
• Boger RH, Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl 2003;4:23-8
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Impraim B, Simmel S, Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-9
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Bode-Boger SM, Frolich JC, Asymmetric dimethylarginine, blood pressure and renal perfusion in elderly subjects. Circulation 2003;107:1891-5
   PubMed Web of Science ®Google Scholar
• Zoccali C, Bode-Boger S, Mallamaci F, Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-17
   PubMed Web of Science ®Google Scholar
• Palloshi A, Fragasso G, Piatti P, Effect of oral l-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise test and normal coronary arteries. Am J Cardiol 2004;93:930-5
   Web of Science ®Google Scholar
• Takiushi S, Fujii H, Kamide K, Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens 2004;17:802-8
   PubMed Web of Science ®Google Scholar
• Perticone F, Sciacqua A, Maio R, Asymmetric dimethylarginine, L-arginine and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005;46:518-23
   PubMed Web of Science ®Google Scholar
• Furuki K, Adachi H, Matsuoka H, Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery. An epidemiological study. Atherosclerosis 2007;191:206-10
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F, Maas R, Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002;62:339-45
   PubMed Web of Science ®Google Scholar
• Krzyzanowska K, Mittermayer F, Shnawa N, Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria. Diabet Med 2007;24:81-6
   PubMed Web of Science ®Google Scholar
• Caglar K, Yilmaz MI, Sonmez A, ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006;70:781-7
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Dimitriadis K, Andrikou E, ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. Am J Kidney Dis 2010;55:1050-9
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Dimitriadis K, Antoniadis D, Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Am J Hypertens 2004;17:470-6
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Dimitriadis K, Chatzis D, Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 2005;96:946-51
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Dimitriadis K, Taxiarchou E, Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens 2006;19:462-6
   PubMed Web of Science ®Google Scholar
• Xiang GD, Pu JH, Zhao LS, Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes. Diabet Med 2009;26:397-403
   PubMed Web of Science ®Google Scholar
• Knudsen ST, Foss CH, Poulsen PL, Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003;149:39-42
   PubMed Web of Science ®Google Scholar
• The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Stefanadis C, Antoniadis D, Absence of any significant effects of circadian blood pressure variations on carotid artery elastic properties in essential hypertensive subjects. J Hum Hypertens 2000;14:813-18
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39:S1-S246
   PubMed Web of Science ®Google Scholar
• Schiller NB, Shah PM, Crawford M, Recommendations for quantitation of the left ventricular dimensions by two-dimensional echocardiography. American Society of Echocardiography Committee on standards, subcommittee on quantitation of the two-dimensional echocardiograms. J Am Soc Echocardiogr 1989;2:358-67
   PubMed Web of Science ®Google Scholar
• Lieb W, Gona P, Larson MG, Biomarkers of the osteoprotegerin pathway clinical correlates, subclinical disease, incident cardiovascular disease and mortality. Arterioscler Thromb Vasc Biol 2010;30:1849-54
   PubMed Web of Science ®Google Scholar
• Caidahl K, Ueland T, Aukrust P. Osteoprotegerin: a biomarker with many faces. Arterioscler Thromb Vasc Biol 2010;30:1684-6
   PubMed Web of Science ®Google Scholar
• Ali Z, Ellington AA, Mosley TH Jr, Kullo IJ. Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. Atherosclerosis 2009;206:575-80
   PubMed Web of Science ®Google Scholar
• Noheria A, Mosley TH, Kullo IJ. Association of serum osteoprotegerin with left ventricular mass in African-American adults with hypertension. Am J Hypertens 2010;23:767-74
   PubMed Web of Science ®Google Scholar
• Omland T, Drazner MH, Ueland T, Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007;49:1392-8
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Borgioni C, Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998;32:983-8
   PubMed Web of Science ®Google Scholar